The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Aspirin Intake and Survival After Breast Cancer
Open accessAbstract
Purpose: Animal and in vitro studies suggest that aspirin may inhibit breast cancer metastasis. We studied whether aspirin use among women with breast cancer decreased their risk of death from breast cancer. Methods: This was a prospective observational study based on responses from 4,164 female registered nurses in the Nurses' Health Study who were diagnosed with stages I, II, or III breast cancer between 1976 and 2002 and were observed until death or June 2006, whichever came first. The main outcome was breast cancer mortality risk according to number of days per week of aspirin use (0, 1, 2 to 5, or 6 to 7 days) first assessed at least 12 months after diagnosis and updated. Results: There were 341 breast cancer deaths. Aspirin use was associated with a decreased risk of breast cancer death. The adjusted relative risks (RRs) for 1, 2 to 5, and 6 to 7 days of aspirin use per week compared with no use were 1.07 (95% CI, 0.70 to 1.63), 0.29 (95% CI, 0.16 to 0.52), and 0.36 (95% CI, 0.24 to 0.54), respectively (test for linear trend, P < .001). This association did not differ appreciably by stage, menopausal status, body mass index, or estrogen receptor status. Results were similar for distant recurrence. The adjusted RRs were 0.91 (95% CI, 0.62 to 1.33), 0.40 (95% CI, 0.24 to 0.65), and 0.57 (95% CI, 0.39 to 0.82; test for trend, P = .03) for 1, 2 to 5, and 6 to 7 days of aspirin use, respectively. Conclusion: Among women living at least 1 year after a breast cancer diagnosis, aspirin use was associated with a decreased risk of distant recurrence and breast cancer death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
A structural approach to selection bias
Hernán, M. A., Hernández-Díaz, S., & Robins, J. M. (2004) · Epidemiology · doi:10.1097/01.ede.0000135174.63482.43 · Cited by 2,844 · cited 1×
“In this case, standard Cox models may lead to biased estimates, whether one does or does not adjust for the potential timedependent confounders.(8) Therefore, we used marginal structural Cox models, which appropriately adjust for measured time-dependent confounding.”
MethodHernán, M. Á., Brumback, B., & Robins, J. M. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00012 · Cited by 1,782
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Choi, H. K., Hernán, M. A., Seeger, J. D., Robins, J. M., & Wolfe, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08213-2 · Cited by 1,127
Bartelink, H., Horiot, J.-C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010874 · Cited by 941
Cook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
Host cyclooxygenase-2 modulates carcinoma growth
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., & DuBois, R. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9621 · Cited by 673
Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments
Hernán, M. A., Brumback, B., & Robins, J. M. (2001) · Journal of the American Statistical Association · doi:10.1198/016214501753168154 · Cited by 493
Dubé, C., Rostom, A., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00009 · Cited by 334
Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
Brewster, A. M., Hortobagyi, G. N., Broglio, K. R., Kau, S.-W., Santa-Maria, C. A., Arun, B., Buzdar, A. U., Booser, D. J., Valero, V., Bondy, M., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn233 · Cited by 331
A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence
Jacobs, E. J., Thun, M. J., Bain, E. B., Rodriguez, C., Henley, S. J., & Calle, E. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk132 · Cited by 322
PROSTAGLANDINS AND BREAST CANCER
Bennett, A., Mcdonald, A. M., Stamford, I. F., Charlier, E. M., Simpson, J. S., & Zebro, T. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92496-5 · Cited by 292
Breast cancer and NSAID use: a meta-analysis
Khuder, S. A., & Mutgi, A. B. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1709 · Cited by 273
Cole, S. R. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg206 · Cited by 270
Antiplatelet therapy for acute ischaemic stroke
Sandercock, P. A., Counsell, C., Gubitz, G. J., & Tseng, M.-C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000029.pub2 · Cited by 260
Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis
Takkouche, B., Regueira-Mendez, C., & Etminan, M. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn324 · Cited by 215
Prospective Study of Regular Aspirin Use and the Risk of Breast Cancer
Egan, K. M., Stampfer, M. J., Giovannucci, E., Rosner, B. A., & Colditz, G. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.988 · Cited by 183
Aspirin and cancer risk: an updated quantitative review to 2005
Bosetti, C., Gallus, S., & Vecchia, C. L. (2006) · Cancer Causes & Control · doi:10.1007/s10552-006-0033-7 · Cited by 118
Kundu, N., Yang, Q., Dorsey, R. M., & Fulton, A. M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1397 · Cited by 117
Gierach, G. L., Lacey, J. V., Schatzkin, A. G., Leitzmann, M. F., Richesson, D. A., Hollenbeck, A. R., & Brinton, L. A. (2008) · Breast Cancer Research · doi:10.1186/bcr2089 · Cited by 106
NSAIDs and breast cancer recurrence in a prospective cohort study
Kwan, M. L., Habel, L. A., Slattery, M. L., & Caan, B. J. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9003-y · Cited by 102
Cook, N. R., Cole, S. R., & Hennekens, C. H. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.11.1045 · Cited by 100
Persell, S. D., Murff, H. J., Roumie, C. L., Spigel, D. R., Jha, A. K., & Horng, M. S. (2005) · Cited by 86
NSAID use and survival after breast cancer diagnosis in post-menopausal women
Blair, C. K., Sweeney, C., Anderson, K. E., & Folsom, A. R. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9277-x · Cited by 84
Nonsteroidal Antiinflammatory Drugs and Breast Cancer Risk: The Multiethnic Cohort
Gill, J. K., Maskarinec, G., Wilkens, L. R., Pike, M. C., Henderson, B. E., & Kolonel, L. N. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm195 · Cited by 66
Current antiplatelet therapies: Benefits and limitations
Angiolillo, D. J., Guzmán, L. A., & Bass, T. A. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.06.003 · Cited by 63
Dang, C. T., Dannenberg, A. J., Subbaramaiah, K., Dickler, M. N., Moasser, M. M., Seidman, A. D., D’Andrea, G. M., Theodoulou, M., Panageas, K. S., Norton, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0463 · Cited by 62
NSAID use and breast cancer risk in the VITAL cohort
Ready, A., Velicer, C. M., McTiernan, A., & White, E. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9665-x · Cited by 61
Mangiapane, S., Blettner, M., & Schlattmann, P. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1503 · Cited by 57
Nonsteroidal Anti-inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women
Hudson, A., Gierach, G. L., Modugno, F., Simpson, J. K., Wilson, J. W., Evans, R. W., Vogel, V. G., & Weissfeld, J. L. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2739 · Cited by 57
Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study
Friis, S., Thomassen, L., Sørensen, H. T., Tjønneland, A. M., Overvad, K., Cronin-Fenton, D. P., Vogel, U. B., McLaughlin, J. K., Blot, W. J., & Olsen, J. H. (2008) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e3282b6fd55 · Cited by 56
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial
Zhang, S. M., Cook, N. R., Manson, J. E., Lee, I.-M. M., & Buring, J. E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604240 · Cited by 55
Sotiriou, C., Lacroix, M., Lagneaux, L., Berchem, G., & Body, J. J. (1999) · PubMed · Cited by 48
Natarajan, K., Mori, N., Artemov, D., Aboagye, E. O., Chacko, V. P., & Bhujwalla, Z. M. (2000) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(99)00026-6 · Cited by 24
Cited by
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Rothwell, P. M., Price, J. F., Fowkes, F. G. R., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61720-0 · Cited by 839
The platelet contribution to cancer progression
BAMBACE, N. M., & HOLMES, C. E. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04131.x · Cited by 705
The impact of comorbidity on cancer survival: a review
Sogaard, M., W. Thomsen, R., Bossen, Henrik Toft Sørensen, H., & Nørgaard, M. (2013) · Clinical Epidemiology · doi:10.2147/clep.s47150 · Cited by 603
Metadata
- Authors
- Holmes, M. D., Chen, W. Y., Li, L., Hertzmark, E., Spiegelman, D., & Hankinson, S. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-03-20
- Volume
- 28
- Issue
- 9
- Pages
- 1467-1472
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114120215
- Cited by
- 365
- References
- 35
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.